| Oxidative stress in chronic kidney disease |
60 |
| Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases |
28 |
| Expert consensus guidelines for the genetic diagnosis of Alport syndrome |
22 |
| New insights into the pathogenesis of IgA nephropathy |
19 |
| A review of the role of immune cells in acute kidney injury |
17 |
| Validation of standardized creatinine and cystatin C GFR estimating equations in a large multicentre European cohort of children |
14 |
| Mitochondrial mechanisms and therapeutics in ischaemia reperfusion injury |
14 |
| Genetic testing in steroid-resistant nephrotic syndrome: why, who, when and how? |
12 |
| Renal function and blood pressure are altered in adolescents born preterm |
12 |
| Acute kidney injury in neonatal encephalopathy: an evaluation of the AWAKEN database |
12 |
| Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study |
11 |
| Pediatric acute kidney injury and the subsequent risk for chronic kidney disease: is there cause for alarm? |
11 |
| Immunology of idiopathic nephrotic syndrome |
11 |
| Central systolic blood pressure and central pulse pressure predict left ventricular hypertrophy in hypertensive children |
10 |
| The gut-kidney axis in IgA nephropathy: role of microbiota and diet on genetic predisposition |
10 |
| Predictive ability of NGAL in identifying urinary tract infection in children with neurogenic bladders |
9 |
| Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS) |
9 |
| COQ2 nephropathy: a treatable cause of nephrotic syndrome in children |
9 |
| Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome |
9 |
| Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus |
9 |
| D-lactic acidosis in humans: systematic literature review |
9 |
| A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis |
9 |
| Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets |
9 |
| Oxidative stress in autosomal dominant polycystic kidney disease: player and/or early predictor for disease progression? |
9 |
| The role of macrophages during acute kidney injury: destruction and repair |
9 |
| Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents |
8 |
| Zebrafish as a model for kidney function and disease |
8 |
| Shiga toxin triggers endothelial and podocyte injury: the role of complement activation |
8 |
| Patent ductus arteriosus is associated with acute kidney injury in the preterm infant |
8 |
| Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy |
8 |
| Emerging biomarkers of chronic kidney disease in children |
8 |
| Educational review: measurement of GFR in special populations |
8 |
| Deriving and understanding the risk of post-transplant recurrence of nephrotic syndrome in the light of current molecular and genetic advances |
7 |
| Incidence, risk factors, and outcome of neonatal acute kidney injury: a prospective cohort study |
7 |
| An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28days to < 6years with chronic kidney disease receiving dialysis |
7 |
| Recurrence of nephrotic syndrome following kidney transplantation is associated with initial native kidney biopsy findings |
7 |
| Hypertensive crisis in children and adolescents |
7 |
| Survival in children requiring chronic renal replacement therapy |
7 |
| D-dimer as a marker of acute pyelonephritis in infants younger than 24 months with urinary tract infection |
7 |
| Diagnosis and management of bladder bowel dysfunction in children with urinary tract infections: a position statement from the International Children's Continence Society |
7 |
| Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study |
7 |
| Using urine nitrite sticks to test for urinary tract infection in children aged < 2 years: a meta-analysis |
7 |
| Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use |
7 |
| Anemia in chronic kidney disease |
7 |
| A clinical predictive model of renal injury in children with congenital solitary functioning kidney |
7 |
| A pediatric neurologic assessment score may drive the eculizumab-based treatment of Escherichia coli-related hemolytic uremic syndrome with neurological involvement |
7 |
| Fluid overload independent of acute kidney injury predicts poor outcomes in neonates following congenital heart surgery |
7 |
| An update on LDL apheresis for nephrotic syndrome |
7 |
| Utilisation of small paediatric donor kidneys for transplantation |
7 |
| HNF1B nephropathy has a slow-progressive phenotype in childhood-with the exception of very early onset cases: results of the German Multicenter HNF1B Childhood Registry |
7 |
